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Abstract
Background: Depression is a prevalent disorder in chronically ill elderly persons. It may decrease quality of life,
and increase functional disability, medical costs, and healthcare utilisation. Because patients may slip into a
downward spiral, early recognition and treatment of depression is important. Depression can be treated with
antidepressants or psychological interventions; the latter can also be applied by trained paraprofessionals.
In this paper, we describe the design of the DELTA study (Depression in Elderly with Long-Term Afflictions). The
first objective of the DELTA study is to evaluate the effectiveness and cost-effectiveness of a minimal psychological
intervention (MPI) to reduce depression in chronically ill elderly patients. The second objective is to evaluate
whether a potential effect of the MPI may differ between types of chronic illnesses. The tailor-made intervention
is administered by nurses, who are trained in the principles of cognitive behavioural therapy and self-management.
Methods/Design: DELTA is a two-armed randomised controlled trial, comparing MPI to usual care. A total
number of 180 patients with diabetes mellitus type II (DM) and 180 patients with chronic obstructive pulmonary
disease (COPD), who in addition suffer from non-severe depression, will be included in the study. In our study,
non-severe depression is defined as having minor depression, mild major depression or moderate major
depression. The primary outcome measure is depression using the Beck Depression Inventory. Secondary
outcome measures include quality of life, daily functioning, self-efficacy, autonomy, and participation. In the
economic evaluation, cost-effectiveness and cost-utility ratios will be calculated. Furthermore, a process
evaluation will be carried out.
Analyses will include both univariate and multivariate techniques and according to the intention to treat principle.
The economic evaluation will be done from a societal perspective and data of the process evaluation will be
analysed using descriptive techniques.
Discussion:  A total number of 361 patients has been included in the study. All interventions have been
administered and follow-up data will be complete in September 2006.
Preliminary results from the process evaluation indicate that patients' satisfaction with the intervention is high. If 
this intervention proves to be effective, implementation of the DELTA intervention is considered and anticipated.
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Background
Depression is a prevalent and disabling disorder, espe-
cially in patients with chronic illnesses, such as diabetes
mellitus type II (DM) and chronic obstructive pulmonary
disease (COPD). In older patients with DM, prevalence
rates of clinical relevant depression range from 14 to 17%
[1,2]. In older patients with COPD, prevalence rates of
25% for minor depression have been reported [3]. Preva-
lence rates of major depression in older COPD patients
range from 6 to 42% [4].
Persons suffering from minor or major depression have
increased mortality risks and a decreased quality of life
compared with non-depressed persons [5-7]. Further-
more, depression has been shown to increase health care
utilisation [8,9], medical costs [10], and disability
[8,9,11]. Since disability predicts the onset of depression
and depression itself may further heighten risks of a pro-
gressing disability, this process of mutual reinforcement
may lead to a downward spiral [11-14]. In addition,
depression impairs one's ability to adhere to disease man-
agement regimens (diet, exercise, quitting smoking, tak-
ing medication regularly), potentially worsening the
course of the chronic illness [15,16]. Hence, an early
detection of depressive symptoms and treatment of
depression is important in chronically ill elderly persons,
thereby preventing or breaking a downward spiral. In pri-
mary care however, depression often remains undetected
[17]. General practitioners have limited time and further-
more, current Dutch guidelines for DM and COPD don't
take into account the psychological consequences of the
chronic illness.
Available treatment options are antidepressants or psy-
chological interventions. The effectiveness of antidepres-
sants has been extensively studied and proven in major
depression [18]. Since there is no clear evidence of the
effectiveness of antidepressants in minor depression
[19,20], clinical guidelines advise against using antide-
pressants in minor depression [21,22]. Cognitive therapy
(CT) seems to be as effective as antidepressants in severe
depression [23], and also in patients with mild and mod-
erate depression [24]. Furthermore, CT seems to have an
enduring effect [25]. It is also increasingly recognised that
chronically ill elderly suffering from depression might
benefit from psychosocial support and improving coping
skills, such as self-management techniques [21,26]. In a
study with DM type II patients, cognitive behavioural
therapy (CBT) in combination with supportive diabetes
education proved to be an effective treatment for major
depression [27]. Similarly, self-management strategies in
COPD patients have been reported to improve the
patients' health status and to reduce hospital admissions
[28].
Accumulating evidence shows that primary care staff can
be trained in psychological interventions for depression
[29]. Several studies reported that practice nurses can suc-
cessfully administer interventions to reduce depression in
primary care settings [30,31].
We developed a minimal psychological intervention
(MPI), based on principles of self-management and CBT.
The intervention is administered by nurses and aims to
reduce non-severe depression in chronically ill elderly
persons. Findings of a prior smaller pilot study showed
that the intervention was feasible and acceptable to
patients. Furthermore, the training programme, devel-
oped to teach nurses to administer the intervention,
appeared to be feasible, attractive and successful among
nurses [32].
In this contribution, we present the design of the DELTA
study (Depression in Elderly with Long-Term Afflictions).
The first objective of this randomised controlled trial
(RCT) is to evaluate the effectiveness and cost-effective-
ness of an MPI that is administered by a nurse and aims to
reduce non-severe depression in chronically ill elderly
patients. The effects of the MPI are compared with usual
care. The second objective is to evaluate whether a poten-
tial effect of the MPI is different between types of chronic
illnesses.
Design and methods
Design
The DELTA study is a two-armed randomised controlled
trial, in which an effect evaluation, an economic evalua-
tion and a process evaluation will be carried out. A total
number of 360 patients will be included, 180 of which are
patients with DM and 180 are patients suffering from
COPD. We chose DM and COPD because first, they are
highly prevalent in primary care. Second, they have a dif-
ferent course and prognosis. DM can be seen a gradual
progressive illness, whereas COPD as a gradual relapsing
condition [33]. This difference enables us to test whether
the intervention is potentially generic. Approval for con-
ducting this study was granted by the Medical Ethics Com-
mittee of the Maastricht University/Academic Hospital
Maastricht.
Setting and recruitment
In general practices in the southern part of Limburg, a
province in the south of the Netherlands, all patients of 60
years and over with DM and or COPD were selected by the
general practitioner, the general practitioner's assistant, or
the research assistant. Selection was made using ICPC
codes (T90, R91.01, R95, R99.06) if possible and other-
wise by medication prescriptions (those drugs which are
most often prescribed by the general practitioner for these
chronic illnesses). In the last phase of patient selection,BMC Public Health 2006, 6:161 http://www.biomedcentral.com/1471-2458/6/161
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the general practitioner applied the inclusion and exclu-
sion criteria using a pre-coded form with checkboxes for
each criterion (Table 1).
All selected patients received a letter from their general
practitioner with a request to complete a short screening
questionnaire. This questionnaire, the Patient Health
Questionnaire-9 (PHQ-9), consists of nine questions
regarding the prevalence of symptoms of depression over
the last two weeks. The response options are: "Not at all",
"Several days", "More than half the days" and "Nearly
every day". Its brevity and the fact that it is a self-adminis-
tered questionnaire make it a useful tool in screening for
depression in primary care. The PHQ-9 has been validated
for both diagnosing depression and measuring severity
[34-36]. Five questions on demographic variables were
included in the questionnaire. Patients received a
reminder by telephone two weeks after the questionnaire
had been sent.
All patients who scored at least 2 depressive symptoms at
least at "more than half the days" and at least one of these
symptoms was depressed mood or anhedonia, were
invited to participate in an interview to confirm or reject
the diagnosis of depression.
The Mini International Neuropsychiatric Interview
(MINI) was used to confirm the diagnosis from the PHQ-
9. The interview took place at the patient's home and was
administered by a trained nurse. The MINI is a validated
and reliable diagnostic structured interview, covering 17
disorders based on DSM-IV criteria [37,38]. An extra diag-
nosis box for minor depression was added to the MINI,
based on the research criteria for minor depression as
described in the DSM-IV [39]. Furthermore, the Hamilton
Depression Rating Scale (HDRS) was used to determine
the severity of the depression [40,41]. Patients were
excluded if they met one of the following criteria: if the
MINI indicated a major depression in combination with a
score above 18 (indicating a severe depression) on the
HDRS, if the MINI indicated suicidal risk, or if the MINI
indicated no depression at all (Table 1). Patients with a
major depression and/or suicidal risk were referred back
to their general practitioner. All remaining eligible
patients (patients with a minor depression, non-severe
major depression, or dysthymia) were invited to partici-
pate in the study and to give their informed consent.
Randomisation
After having signed the informed consent form, patients
enrolled in the study and filled in the baseline question-
naire. After having completed the baseline questionnaire,
patients were assigned to either the intervention or con-
trol group. Randomisation was performed by an external
agency using a computerized random number generator.
In order to avoid an imbalance of chronic illness and gen-
eral practice (care level) over the two groups, stratification
for general practice and chronic illness (DM or COPD)
was performed. Furthermore, to obtain equal numbers in
both arms, a blocked design with a block size of two was
applied. The intervention group received a Minimal Psy-
chological Intervention, while the control group received
usual care as given by their general practitioner, according
to the guidelines for the specific chronic illness.
Minimal Psychological Intervention
The intervention was given by a trained nurse, at the
patient's own home. During a period of at most three
Table 1: Inclusion and exclusion criteria as applied by the general practitioner* or research nurse†
Inclusion criteria:
Established diagnosis of Diabetes Mellitus Type II or COPD*
Age 60 years and over*
Community dwelling*
Minor depression or mild to moderate major depression according to MINI and HDRS criteria†
Completed informed consent†
Exclusion criteria:
Treatment with antidepressants*†
Severe major depression*†
Major psychiatric problems (bipolar depression, schizophrenia, suicidal risk)*†
Current psychosocial/psychiatric treatment*
Serious cognitive problems (demential syndrome)*
On waiting list for nursing home*
Bedridden*
Recent loss of spouse (< 3 months)*BMC Public Health 2006, 6:161 http://www.biomedcentral.com/1471-2458/6/161
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months, patients received a maximum of 10 visits from
the nurse. The number of visits depended on the patient's
progress.
The Minimal Psychological Intervention contains ele-
ments from the Chronic Disease Self-Management Pro-
gram (CDSMP) by Lorig and Gonzales [42], the
Reattribution model from Goldberg [43] and from the
work of the project group of the Interventie Studie Eerste
Lijn (INSTEL) [44], as previously described [32]. The
intervention aims at teaching patients to take responsibil-
ity for day-to-day management of their illness and its con-
sequences. In short, it consists of five phases:
Phase 1. The nurse explores the patient's cognitions on the
origin of symptoms and complaints, and their relation to
limitations and behaviour.
Phase 2: The patient keeps a diary, where he or she records
symptoms, complaints, thoughts, worries, related feel-
ings, and behaviour.
Phase 3: Using information from the diary, the nurse chal-
lenges the patient to link his or her mood and consequent
behaviour to the course of the chronic illness. A distinc-
tion will be made between complaints related to the ill-
ness itself, and those related to the emotional and
behavioural consequences of the illness.
Phase 4: Introduction of the self-management approach
by the nurse. The patient explores his or her possibilities
to alter his or her behaviour. He or she then makes a plan
on how to solve perceived problems and sets specific goals
to be reached before the next visit from the nurse.
Phase 5: Evaluation of the progress in achieving the goals.
After a patient has completed these five phases success-
fully, he or she is supposed to be able to apply the self-
management approach to any situation or problem he or
she may encounter in the future. In consultation with the
patient, the nurse can then decide to conclude the series of
intervention visits.
The training program for nurses
Administering the MINI
In an 8 h session, the nurses were trained how to confirm
a diagnosis of depression by using the MINI and HDRS by
a psychiatrist.
Applying the Minimal Psychological Intervention
During three 8 h sessions, with 2-week intervals, four
nurses were trained by two experienced trainers (a psy-
chologist/cognitive behaviour therapist, and a general
practitioner) on how to apply the intervention. In
between training days, nurses practised their newly
learned skills on a pilot patient. As mentioned earlier, the
training program has been shown to be feasible, attractive
and successful among nurses [32]. Booster sessions were
being held regularly during the study, and both a psychi-
atrist and a psychologist could be contacted by telephone
to discuss cases at any time.
Data collection
Data was collected at five points in time: at baseline (T0),
one week after the intervention period (T1), and at three,
six and nine months after the intervention period (T2, T3,
T4) (Fig. 1). The intervention period for patients allocated
to the intervention group varies from one week to three
months. The intervention period of the control group is
fixed at six weeks, which is estimated to be the mean dura-
tion of the intervention period in the intervention group.
Data were collected using self-administered question-
naires and cost diaries in combination with interviews by
telephone.
Effect evaluation
Table 2 provides an overview of the measures of the effect
and economic evaluation, and time of assessment.
Primary outcome measures
The primary outcome measure in this study was level of
depression, measured with the Beck Depression Inventory
(BDI) [45,46]. The BDI consists of 21 items measuring
symptoms of depression and has proven to be a valid and
reliable tool [47].
Secondary outcome measures
Secondary outcome measures in the study were: Quality
of life measured with the Short Form-36 (SF-36) [48], dis-
ease-specific quality of life assessed with the Problem
Areas in Diabetes questionnaire (PAID-1) [49] for diabe-
tes patients, and the St. George's Respiratory Question-
naire (SGRQ) for patients with pulmonary disease
[50,51]. Furthermore, daily functioning was assessed with
the Activities of Daily Life scale (ADL) from the Gronin-
gen Activity Restriction Scale (GARS) [52], self-efficacy
assessed using the 12-item Self-efficacy scale [53,54] and
autonomy and participation using the questions from the
domain Autonomy outdoors from the Impact on Partici-
pation and Autonomy questionnaire (IPA) [55,56].
Covariates
Additionally, information on possible confounding fac-
tors and effect modifiers was collected. Information on
demographic factors (age, gender, marital status, religion,
education, occupation) was collected in the screening
phase. Other factors measured are: coping using the active
coping, avoidant coping and passive coping scales from
the Utrecht Coping List (UCL) [57], mastery using the Per-BMC Public Health 2006, 6:161 http://www.biomedcentral.com/1471-2458/6/161
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sonal Mastery Scale developed by Pearlin and Schooler
[58], anxiety assessed using the anxiety subscale from the
Symptom Checklist (SCL-90) [59], social support using
the short version of the Social Support List- Interactions
questionnaire (SSL-I) [60,61], co-morbidity using the
Chronic conditions list from Statistics Netherlands (CBS –
Centraal Bureau voor de Statistiek), life events using a list
of 16 life events where patients report which life events
they have experienced in the past year, and how they value
these events (positive, negative, or neutral). Personality
was measured using scales for neuroticism and extraver-
sion from the Eysenck Personality Questionnaire (EPQ)
[62]; severity of the chronic illness was assessed using the
St. George's Respiratory Questionnaire (SGRQ) for COPD
patients [50,51], and the Diabetes Symptom Checklist –
Revised (DSC-R) for diabetes patients [63]. If possible,
severity of the chronic illness will also be assessed by
retrieving lung function (FEV1) and/or blood glucose lev-
els (Hba1c) from hospital records or the general practi-
tioner's records at the end of the study Finally, smoking
and body mass index (BMI) were assessed, and in order to
check for contamination in the control group, two ques-
tions to check whether or not the patients in the control
group had heard or benefited from the intervention were
added to the questionnaire. Contamination of the control
group may lead to a smaller difference in effect between
intervention and control group.
Economic evaluation
A combined cost-effectiveness/cost-utility analyses will be
performed from a societal perspective. The BDI is used as
primary outcome measure in the cost-effectiveness analy-
ses. The primary outcomes measure for the cost-utility
measure will be utilities based on the social tariff of the
EuroQol [64]. Healthcare costs, patient and family costs,
as well as productivity losses will be recorded using cost
diaries [65]. Patients prospectively kept the diary for two
weeks at baseline and for four weeks at each follow up
measurement. Afterwards, a telephonist contacted them
to retrieve the information from the diary. Data were
immediately entered in a computer file to ensure effi-
ciency and reliability. The costs of the intervention were
separately calculated. For the valuation of health care
costs and patient and family costs, the updated Dutch
Guideline for costing in economic evaluations [66] will be
used. If no guideline costs existed, cost prizes were esti-
mated using real costs and tariffs. For future costs and
effectiveness data, a discount rate of 4% will be used.
Process evaluation
A process evaluation was carried out to assess the follow-
ing outcomes. The reach of the intervention, defined as
the proportion of the intended target population that
actually participated in the intervention. The dose deliv-
ered was defined as the completeness of the intervention
DELTA flowchart Figure 1
DELTA flowchart. Q = questionnaire, 2 w CD = two 
week cost diary, 4 w CD = four week cost diary * First fol-
low up takes place one week after the intervention period. In 
the intervention group, this may vary from 2 weeks to three 
months. In the control group, the intervention period is fixed 
at six weeks, which is estimated to be the mean duration of 
the intervention in the intervention group.
9 month
Follow up
(Q + 4w CD)
Intervention group Control group
Screening
(PHQ)
MINI + HDRS
Informed
consent
Baseline
(Q+2w CD)
1 week *
Follow up
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and number and duration of the intervention visit. Dose
received, described in two concepts, namely exposure and
satisfaction. Exposure is the extent to which patients
actively engage with and are receptive to the intervention,
and satisfaction is defined as patient's satisfaction with the
intervention [67]. Barriers were described as the extent in
which problems were encountered during the interven-
tion.
Data were collected using questionnaires filled out by
nurses after every intervention visit, by means of checklists
that were kept by the nurse for every patient to report
which steps of the intervention had been taken, and by
questionnaires filled out by patients after finishing the
intervention.
Analysis
Data will be analysed according to the intention to treat
principle. In addition, on treatment analyses will be per-
formed. Changes in primary and secondary outcome
measures between intervention and control group will be
analysed using both univariate and multivariate tech-
niques. Models will be adjusted for age, gender and socio-
economic status (SES), and baseline differences. Potential
additional confounding factors and effect modifiers will
be checked and, if necessary, included in the model. Since
dependency between observations of subjects from the
same general practice may exist as well as between
repeated observations within persons, multilevel analyses
will also be carried out.
Table 2: Outcome measures and time of assessment in the DELTA study
Measure Moment in time
Name questionnaire/variable Screening Baseline FU1 FU2 FU3 FU4 Other
Marital status/living situation x - - - - - -
Occupation/work situation x - - - - - -
Education x - - - - - -
G e n d e r x - ---- -
Age x - - - - - -
Religion x - - - - - -
BDI - x x x - x -
Euroqol (QALY's) - x x x - x -
SF36 - x x x - x -
SGRQ - x x x - x -
PAID-1 - x x x - x -
ADL-scale from GARS - x x x - x -
SF36 - x x x - x -
UCL - x x x - x -
Personal mastery scale - x x x - x -
Self-efficacy-scale - x x x - x -
IPA - x x x - x -
SCL-90 subscale anxiety - x x x - x -
SSL-I 12 - x - - - x -
CBS List Chronic conditions - x - - - x -
Diabetes Symptom Checklist-Revised - x x x - x -
Life-events - - - - - x -
EPQ - - x - - - -
Year of diagnosis DM/COPD - x - - - - -
Smoking - - - - - x -
BMI - - - - - x -
Contamination in control group - - - - - x -
Direct costs within health care system - x x x x x -
Direct costs outside health care system - x x x x x -
Indirect costs outside health care system - x x x x x -
Lung function – if available - - - - - - After intervention
Hba1c – if available - - - - - - After intervention
Process evaluation - - - - - - During nurses training program and intervention period
Compliance (in process-evaluation) - - - - - - During intervention period
FU = follow upBMC Public Health 2006, 6:161 http://www.biomedcentral.com/1471-2458/6/161
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All analyses will be performed for intervention and con-
trol group in total, as well as for DM and COPD sepa-
rately.
In the economic evaluation the cost and effects of care as
usual and MPI by a practice nurse will be calculated and
compared. The cost-effectiveness ratio will be stated in
terms of costs per improvement on the BDI, the cost-util-
ity ratio will focus on the net cost per QALY gained. Ratios
will be determined for the total patient population as well
as for COPD or DM patients separately. Bootstrapping
will be used to estimate confidence intervals for calculated
ratios.
Descriptive statistics, Chi-square and t-tests will be used to
analyse data from the process evaluation.
Power calculation
Assuming an α of 0.05, a 1 – β (power) of 0.90, a decrease
of 18 percent of non-severe depression in the intervention
group versus zero percent in the control group, 192 per-
sons were needed [68]; 48 COPD and 48 DM patients in
the intervention group and 48 COPD and 48 DM patients
in the control group. We decided to recruit four groups of
90 patients (in total: 360), as we not only anticipated the
potential need for sub-group specific analyses, but also
anticipated attrition varying between 20 and 30 percent
(e.g. due to refusals during the follow-up).
Discussion
Progress of the study
Based on experiences in the pilot study, we anticipated
having to screen 3600 patients in order to include 360
patients. However, we had to increase the number of
patients to be screened to reach this number. This was
done because the percentage of patients eligible for the
MINI interview was lower than in the pilot study. Further-
more, the percentage of patients refusing the MINI inter-
view was higher than expected. To arrive at a gross number
of 360 patients we had to screen a total number of 8326
patients. The response rate to the screening questionnaire
was 67%. Eventually, 361 non-severely depressed patients
were recruited in the study (DM: N = 184; COPD: N =
177). All interventions have been administered; currently
follow-up data are being collected. Data collection will be
complete in September 2006.
Process evaluation
First results of the process evaluation indicate that
patients' satisfaction with the intervention is high, and
96.5% of the patients who received the intervention
reported to have benefited from the intervention.
Future implementation
If this intervention proves to be effective in reducing
depression and improving quality of life and proves to be
cost-effective, implementation of the intervention in the
health care system is considered and anticipated. An
implementation and dissemination plan has been devel-
oped and is regularly being updated to the latest insights.
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